(Total Views: 909)
Posted On: 06/26/2022 1:19:36 AM
Post# of 153908
Quote:
Resmetirom reduced MRI-PDFF and LDL-C and other atherogenic lipids in patients with NASH cirrhosis and reduced FibroScan controlled attenuation parameter (CAP), VCTE, and MRE in a significant fraction of patients.
https://www.globenewswire.com/news-release/20...gress.html
My earlier conclusions still hold true.
Quote:
Resmetirom's fibrosis 50% of the patients as measured by MRE - 15% reduction, as measured by Fibroscan 20%. The problem is what was the % across all patients?
https://investorshangout.com/post/view?id=6331942
(7)
(0)
